

Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
(NEMROCK) International Publications

Clinical Oncology Department

2013

1. Alshemmari SH, Elbasmi AA, **Alsirafy SA**. The place of death of patients with cancer in Kuwait. **BMJ Support Palliat Care**, 2013 (Epub, doi:10.1136/bmjspcare-2012-000433)
2. Al-Zahrani AS, **El-Kashif AT**, Haggag RM, **Alsirafy SA**. Pattern of cancer deaths in a Saudi tertiary care hospital. **Am J Hosp Palliat Care**. 2013; 30(1): 21-24.
3. **Azim H**, Azim HA Jr. Targeting RANKL in breast cancer: bone metastasis and beyond. **Expert Rev Anticancer Ther**. 2013; 13(2): 195-201.
4. **Azim HA**, Kamal NS, **Malak RA**. Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! **J Thorac Dis**. 2013; 5(Suppl 1):S27-35.
5. El-Dahshan DH, Omar MS, Genena AM, **Zawwam HM**. Fibroblast growth factor receptor 3 gene expression in Egyptian acute leukemia patients. **Comparative Clinical Pathology**. 2013 (Epub, doi: 10.1007/s00580-013-1778-5).
6. El Husseiny NM, **Kasem N**, **El Azeem HA**, Mattar MW. Multiple myeloma: a descriptive study of 217 Egyptian patients. **Ann Hematol**. 2013. [Epub ahead of print]
7. **El-Metnawy WH**, Mattar MM, El-Nahass YH, Samra MA, Abdelhamid HM, Abdelfattah RM, Hamed AR. Predictive Value of Pretreatment BCR-ABL(IS) Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic Myeloid Leukemia(CPCML). **Int J Biomed Sci**. 2013; 9(1): 48-53.
8. Ghanem HM, Abou-Alia AM, **Alsirafy SA**. Prevalence of Methicillin-resistant *Staphylococcus aureus* colonization and infection in hospitalized palliative care cancer patients. **Am J Hosp Palliat Care**. 2013; 30(4): 377-379.
9. **Habib EE**, **Fahmy ES**. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. **Clin Transl Oncol**. 2013 Feb 14. [Epub ahead of print]
10. **Ibrahim N**, **Abou-Elela E**, **Darwish D**. Survival of mesothelioma in a palliative medical care unit in Egypt. **Asian Pac J Cancer Prev**. 2013; 14(2):739-742.
11. **Kader YA**, **El-Nahas T**, **Sakr A**. Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. **Onco Targets Ther**. 2013; 6:1073-1077.
12. **Kader YA**, Le Chevalier T, **El-Nahas T**, **Sakr A**. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. **Onco Targets Ther**. 2013; 6: 803-809.

13. **Kader YA**, Spielmann M, **El-Nahas T**, **Sakr A**, Metwally H. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. **Breast Cancer: Targets and Therapy**, 2013, 5:37-42.
14. Khorshied MM, **Said WA**, Shaaban HM. Clinical implication of nucleophosmin gene mutation and Flt-3 internal tandem duplication in a cohort of Egyptian AML patients. **Comparative Clinical Pathology**. 2013: 1-10.
15. **Mansour M**, Mourad C. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. **Cancer Chemother Pharmacol**. 2013; 72(2): 429-435.
16. **Meshref M**, ElShazly N, Nasr M, AbdElhai R. Effect of different doses of prophylactic cranial irradiation in childhood lymphoblastic leukemia on CNS relapse, late cognitive decline and learning disabilities. **J Cancer Therapeutics Research**. 2013; 2:10.
17. **Zwam HM**, **Habib EE**, **AL-Daly ME**. Involved Nodal Radiotherapy vs. Involved Field Radiotherapy after Chemotherapy in the Treatment of Early Stage Hodgkin's Lymphoma. **J Cancer Ther**. 2013; 4: 271-279.

2012

18. Alshemmari S, Ezzat H, **Samir Z**, Refaat S, **Alsirafy SA**. The palliative prognostic index for the prediction of survival and in-hospital mortality of patients with advanced cancer in Kuwait. **J Palliat Med**. 2012; 15(2):200-4.
19. Alshemmari SH, Refaat SM, Elbasmi AA, **Alsirafy SA**. Representation of expatriates among cancer patients in Kuwait and the need for culturally-competent care. **J Psychosoc Oncol**. 2012; 30(3):380-5.
20. **Alsirafy SA**, **Ibrahim NY**, **Abou-Elela EN**. Opioid consumption before and after the establishment of a palliative medicine unit in an Egyptian cancer center. **J Palliat Care**. 2012; 28(3):135-40.
21. **Alsirafy SA**, Mousa SM, Brown SM. Palliative care: an unexplored aspect of schistosomiasis neglect? **Am J Hosp Palliat Care**. 2012; 29(1):7-8.
22. Al-Zahrani AS, **El-Kashif AT**, Mohammad AA, Elsamany S, **Alsirafy SA**. Prediction of in-hospital mortality of patients with advanced cancer using the Chuang's Prognostic Score. **Am J Hosp Palliat Care**, 2012 (Epub, doi: 10.1177/1049909112467362)
23. Arnaout HH, Khorshied MM, Shaheen IA, Gouda HM, **Ibrahim NY**, Koura NF. The clinical significance of methylenetetrahydrofolate reductase (MTHFR) polymorphisms in acute lymphoblastic leukemia. **Comp Clin Pathol**. 2012; 21(1): 39-47.
24. **Azim HA**, Azim HA. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. **Future Oncol**. 2012; 8(2):135-44.
25. **El-Ghoneimy EG**, **Hassan MA**, El-Bestar MF, Othman OM, **Mashhour K N**. A dosimetric comparative study between conformal and intensity modulated radiation therapy in the treatment of primary nasopharyngeal carcinomas: the Egyptian experience. **The Chinese-German Journal of Clinical Oncology**, 2012; 11(11): 626-631.

26. Farawela H, Khorshied M, Shaheen I, Gouda H, Nasef A, Abulata N, Mahmoud HA, **Zawam HM**, Mousa SM. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt. **Infect Genet Evol.** 2012; 12(6):1189-94.
27. **Habib EE**, **El-Kashef AT**, **Fahmy ES**. Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience. **Oncology Reviews** 2012; 6:e3.
28. Huober J, Fasching PA, Barsoum M, Petruzella L, Wallwiener D, Thomssen C, Reimer T, Paepke S, **Azim HA**, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. **Breast.** 2012; 21(1):27-33.
29. **Ibrahim NY**, Sami RM, Nasr AS. *GSTP1* and *CYP1A1* Gene Polymorphisms and Non-Hodgkin Lymphoma. **Lab Medicine** 2012; 43:22-6.
30. Koeck J, **Abo-Madvan Y**, Eich HT, Stieler F, Fleckenstein J, Kriz J, Mueller RP, Wenz F, Lohr F. Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease. **Strahlenther Onkol.** 2012; 188(8):653-659.
31. Koeck J, **Abo-Madvan Y**, Lohr F, Stieler F, Kriz J, Mueller RP, Wenz F, Eich HT. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. **Int J Radiat Oncol Biol Phys.** 2012; 83(1):268-76.
32. Kohail H, Shehata S, Mansour O, Gouda Y, Gaafar R, Hamid TA, El Nowieam S, AlKhadary A, El Zawahry H, Wareth AA, Halim IA, Taleb FA, **Hamada E**, Barsoum M, **Abdullah M**, **Meshref M**. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. **Hematol Oncol Stem Cell Ther.** 2012;5(1):42-8.
33. Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, **Azim HA**, El-Husseiny G, Al-Husaini H, Liu Z. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. **BMC Cancer.** 2012; 12:423.
34. Nasr AS, Sami RM, **Ibrahim NY**. Methylene tetrahydrofolate reductase gene polymorphisms (677C > T and 1298A > C) in Egyptian patients with non-Hodgkin lymphoma. **J Cancer Res Ther.** 2012; 8(3): 355-360.
35. Nassef AA, **Ibrahim NY**. Allelic HER-2 codon 655 polymorphism and the influence of plasma HER-2 levels in breast cancer Egyptian female patients. **Comparative Clinical Pathology.** 2012; 1-5.
36. Neumaier C, Blank E, Welzel G, **Abo-Madvan Y**, Kraus-Tiefenbacher U, Keller A, Gerhardt A, Sütterlin M, Wenz F. TARGIT-E(elderly) - Prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. **BMC Cancer.** 2012; 12(1):171.
37. Shaheen I, **Ibrahim N**. Detection of orphan receptor tyrosine kinase (ROR-1) expression in Egyptian pediatric acute lymphoblastic leukemia. **Fetal Pediatr Pathol.** 2012; 31(3):113-9.
38. Simeonova A, **Abo-Madvan Y**, **El-Haddad M**, Welzel G, Polednik M, Boggula R, Wenz F, Lohr F. Comparison of anisotropic aperture based intensity modulated radiotherapy with 3D-conformal radiotherapy for the treatment of large lung tumors. **Radiother Oncol.** 2012; 102(2):268-73.

2011

39. **Alsirafy SA, El Mesidy SM, Abou-Elela EN, Elfaramawy YI.** Naproxen test for neoplastic fever may reduce suffering. **J Palliat Med.** 2011; 14(5):665-7.
40. **Alsirafy SA, El-Mesidi SM, El-Sherief WA, Galal KM, Abou-Elela EN, Aklan NA.** Opioid needs of patients with advanced cancer and the morphine dose-limiting law in Egypt. **J Palliat Med.** 2011; 14(1):51-4.
41. **Azim HA, Bahr SA, Koura MA, Gad H, Farouk M, Morsy A, Iskander I, Hammad A, Fat'hy M, Attia H, Sadek K.** Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor. **Case Rep Oncol.** 2011; 4(3):467-9.
42. Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, **Azim H,** Peccatori FA. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. **Eur J Cancer.** 2011; 47(1):74-83.
43. El Karakasy SM, El Guindy NM, Gouda HM, Khorshied MM, Shaheen IA, Abu Khalil RE, **Ibrahim NY.** Clinical relevance of angiopoietin-1, angiopoietin-2, and their receptor Tie-2 expression in acute myeloid leukemia. **Comp Clin Pathol.** 2011; 20(4): 341-7.
44. El Saghir NS, El-Asmar N, Hajj C, Eid T, Khatib S, Bounedjar A, Ajarim D, Shamseddine A, Geara F, Jazieh A, **Azim HA, Abdelkader Y,** Kattan J, Abulkhair O. Survey of utilization of multidisciplinary management tumor boards in Arab countries. **Breast.** 2011; 20 Suppl 2:S70-4.
45. **Galal KM,** Khaled Z, Mourad AM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. **Indian J Cancer.** 2011; 48(1):47-54.
46. Ghanem HM, Shaikh RM, Alia AM, Al-Zayir AS, **Alsirafy SA.** Pattern of referral of noncancer patients to palliative care in the eastern province of Saudi Arabia. **Indian J Palliat Care.** 2011; 17(3):235-7.
47. Li CT, Marek M, Guclu SZ, Kim Y, **Meshref M,** Qin S, Kadziola Z, Krejcy K, Altug S. Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. **J Cancer.** 2011; 2:52-61.
48. Mohsen TA, Zeid AA, **Meshref M,** Tawfeek N, Redmond K, Ananiadou OG, Haj-Yahia S. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. **Eur J Cardiothorac Surg.** 2011; 40(2):282-6.
49. Sabry NA, **Habib EE.** Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study. **Med Oncol.** 2011; 28(2):584-90.
50. Sadek HA, **El-Metnawey WH,** Shaheen IA, Korshied MM, **Mohamed AS.** Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts in Egyptian acute lymphoblastic leukemia patients. **J Investig Med.** 2011; 59(8):1258-62.
51. Sami RM, Nasr AS, **Ibrahim NY, Darweesh DO,** El Hussieny NM. Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survival. **Comp Clin Pathol** 2011, DOI: 10.1007/s00580-011-1307-3.

2010

-
52. Al-Shahri MZ, Sroor MY, **Alsirafy SA**. The impact of implementing referra criteria on the pattern of referrals and admissions to a palliative care program in Saudi Arabia. **J Support Oncol**. 2010; 8(2):78-81.
 53. Alshemmari S, Ezzat H, Samir Z, Sajnani K, **Alsirafy S**. Symptom burden in hospitalized patients with cancer in kuwait and the need for palliative care. **Am J Hosp Palliat Care**. 2010; 27(7):446-449.
 54. **Alsirafy SA**. Dealing with barriers to cancer pain control in Egypt. **Eur J Palliat Care**. 2010; 17(1): 10-1.
 55. **Alsirafy SA**. Regulations governing morphine prescription in Egypt: an urgent need for modification. **J Pain Symptom Manage**. 2010; 39(1):e4-6.
 56. **Alsirafy SA**, **El Mesidy SM**, **Abou-Elela EN**. Where do Egyptian palliative care patients with cancer die? **Am J Hosp Palliat Care**. 2010; 27(5):313-5.
 57. **Alsirafy SA**, **El Mesidy SM**, **Abou-Elela EN**, **El Faramawy YI**. Pain prevalence in advanced cancer patients in Egypt. **Eur J Palliat Care**. 2010; 17(6): 303-5.
 58. **Alsirafy SA**, Sroor MY, Al-Shahri MZ. Referral timing of in-hospital cancer deaths to palliative care in a Saudi tertiary care hospital. **Prog Palliat Care**. 2010; 18(2): 85-8.
 59. **Azim H**, Azim HA Jr, Escudier B. Targeting mTOR in cancer: renal cell is just a beginning. **Target Oncol**. 2010; 5(4):269-80.
 60. **Azim HA**, Jazieh AR, Jahanzeb M. The Abu Dhabi declaration: why the hustle? **J Natl Compr Canc Netw**. 2010; 8 Suppl 3:S2-4.
 61. **Azim HA**, Santoro L, Bociek RG, Gandini S, **Malek RA**, Azim HA Jr. High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. **Ann Oncol**. 2010; 21(5):1064-71.
 62. Azim HA Jr, **Azim H**, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. **Expert Rev Clin Immunol**. 2010; 6(6):821-6.
 63. Bazarbachi A, **Azim HA**, Alizadeh H, Aljurf M, Barista I, Chaudhri NA, Fahed Z, Fahmy OA, Ghavamzadeh A, Khalaf MH, Khatib S, Kutoubi A, Paydas S, Elayoubi HR, Zaatari G, **Zawam HM**, Zelenetz AD; MENA Lymphoma Regional Guidelines Committee. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region. **J Natl Compr Canc Netw**. 2010; 8 Suppl 3:S29-35.
 64. Gheita TA, Ezzat Y, Sayed S, El-Mardenly G, **Hammam W**. Musculoskeletal manifestations in patients with malignant disease. **Clin Rheumatol**. 2010; 29(2):181-8.
 65. Jazieh AR, **Azim HA**, McClure J, Jahanzeb M. The process of NCCN guidelines adaptation to the Middle East and North Africa region. **J Natl Compr Canc Netw**. 2010; 8 Suppl 3:S5-7.
 66. Shehata S, Saad E, Goda Y, **El-Mesidi S**, Koheil H, Elzawhri H, Kandeel A, Abdelhamid T, Zaki M, **Meshref M**. A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer. **Hematol Oncol Stem Cell Ther**. 2010; 3(1):1-6.
 67. Zaghoul MS, Boutrus R, El-Hossieny H, **Kader YA**, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. **Int J Clin Oncol**, 15(4):382-389; 2010.
-

2009

68. **Alsirafy SA**. For a peaceful cancer death in Egypt: palliative care is not... **Am J Hosp Palliat Care**. 2009 Dec-2010 Jan; 26(6):502-3.
69. **Azim H**, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. **Cancer Treat Rev**. 2009; 35(7):633-8.
70. Azim HA Jr, Elattar I, Loberiza FR Jr, **Azim H**, Mok T, Ganti AK. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. **Lung Cancer**. 2009; 64(2):194-8.
71. Boggula R, Lorenz F, **Abo-Madyan Y**, Lohr F, Wolff D, Boda-Heggemann J, Hesser J, Wenz F, Wertz H. A new strategy for online adaptive prostate radiotherapy based on cone-beam CT. **Z Med Phys**. 2009; 19(4):264-76.
72. Gabal S, Ashour Z, Hamada G, Aziz SA, Khairy H, Badawy H, **Hamada EM**, Saied K. Low-grade endometrial stromal sarcoma with intravenous extension to the heart. **Medscape J Med**. 2009; 11(1):23.
73. Lohr F, **El-Haddad M**, Dobler B, Grau R, Wertz HJ, Kraus-Tiefenbacher U, Steil V, **Madyan YA**, Wenz F. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. **Int J Radiat Oncol Biol Phys**. 2009; 74(1):73-80.
74. Mahmoud HK, El Nahas Y, Abdel Moaty M, Abdel Fattah R, El Emary M, **El Metnawy W**. Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival. **Int J Biomed Sci**. 2009; 5(3):223-228.
75. Stieler F, Wolff D, Lohr F, Steil V, **Abo-Madyan Y**, Lorenz F, Wenz F, Mai S. A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT). **Radiat Oncol**. 2009; 4:48.
76. Wolff D, **Abo-Madyan Y**, Dobler B, Lohr F, Mai S, Polednik M, Wenz F. Serial tomotherapy vs. MLC-IMRT (multileaf collimator intensity modulated radiotherapy) for simultaneous boost treatment large intracerebral lesions. **Z Med Phys**. 2009; 19(1):58-66.
77. Wolff D, Stieler F, Welzel G, Lorenz F, **Abo-Madyan Y**, Mai S, Herskind C, Polednik M, Steil V, Wenz F, Lohr F. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. **Radiother Oncol**. 2009; 93(2):226-33.

2008

78. **AbdelSalam M**, El Sissy A, Samra MA, Ibrahim S, El Markaby D, Gadallah F. The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia. **Hematology**. 2008; 13(3):147-53.
79. **Abo-Madyan Y**, Polednik M, Rahn A, Schneider F, Dobler B, Wenz F, Lohr F. Improving dose homogeneity in large breasts by IMRT: efficacy and dosimetric accuracy of different techniques. **Strahlenther Onkol**. 2008 Feb;184(2):86-92.
80. **Azim H**, Azim HA Jr. Targeting Her-2/neu in breast cancer: as easy as this! **Oncology**. 2008; 74(3-4):150-7.

81. **Hassan E, Galal K, Esmat E.** Neo-adjuvant Docetaxel and Cisplatin followed by concurrent Cisplatin with radiation therapy in treatment of locally advanced nasopharyngeal carcinoma. **Gulf J Oncolog.** 2008; (3):46-53.

2007

82. **Azim HA,** Elsedewy E, Azim HA Jr. Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature. **Onkologie.** 2007; 30(7):381-4.
83. Eyada TK, **El Ghonemy EG,** El Ghoroury EA, El Bassyouni SO, El Masry MK. Study of genetic polymorphism of xenobiotic enzymes in acute leukemia. **Blood Coagul Fibrinolysis.** 2007; 18(5):489-95.
84. Polednik M, **Abo Madyan Y,** Schneider F, Wolff D, Bannach B, Lambrecht U, Wallin A, Cwiekala M, Maurer K, Reif F, Lohr F, Wenz F; Breast Cancer Working Group (German Cancer Association). Evaluation of calculation algorithms implemented in different commercial planning systems on an anthropomorphic breast phantom using film dosimetry. **Strahlenther Onkol.** 2007; 183(12):667-72.
85. Saied GM, **El-Metenawy WH,** Elwan MS, Dessouki NR. Urine carcinoembryonic antigen levels are more useful than serum levels for early detection of Bilharzial and non-Bilharzial urinary bladder carcinoma: observations of 43 Egyptian cases. **World J Surg Oncol.** 2007; 5:4.
86. **Salam MA, Elnahas T,** Azim HA, **Alsirafy S.** The effect of EGFR overexpression in inoperable non-small cell lung cancer (NSCLC) patients receiving cisplatin-vinorelbine combination. **Turk J Cancer.** 2006; 36 (1): 11-8.

2005

87. Fogliata A, Nicolini G, Alber M, Asell M, Dobler B, **El-Haddad M,** Hårdemark B, Jelen U, Kania A, Larsson M, Lohr F, Munger T, Negri E, Rodrigues C, Cozzi L. IMRT for breast. a planning study. **Radiother Oncol.** 2005; 76(3):300-10.

2001

88. Meir H, Balawi I, **Nayel H,** El Karaksy H, El Haddad A. Hepatic dysfunction in children with acute lymphoblastic leukemia in remission: relation to hepatitis infection. **Med Pediatr Oncol.** 2001; 36(4):469-73.

2000

89. Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, **Azim HA,** Bapsy PP, Buyukkececi F, Chaimongkol B, Chen PM, Cheong SK, Ferhanoglu B, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwivat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarzer AP, Song HS, Suh CW, Suharti C, Supindiman I, Tee GY, Thamprasit T, Villalon AH, Wickham NR, Wong JE, Yalcin A, Jootar S; International Oncology Study Group NHL1 Study. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study. **Leuk Lymphoma.** 2000; 40(1-2):95-103.

1999

-
90. Shafik A, **El-Metnawy W**, El-Sibai O. Anal submucosal injection: a novel modality for the treatment of advanced rectal cancer. *Eur J Surg Oncol*. 1999 Feb;25(1):76-81.
-

1996

91. **Azim HA**. Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study. *J Infus Chemother*. 1996; 6(2):102-6.
-

1994

92. Shafik A, el Dawi M, **el-Metnawy W**. Anal submucosal injection: methotrexate concentration in rectal tumor tissue and serum after anal compared with parenteral injection. *Anticancer Drugs*. 1994; 5(6):650-4.
-

1992

93. **Navel H, el-Ghoneimy E, el-Haddad S**. Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. *Nutrition*. 1992; 8(1):13-8.
-

1991

94. **el-Ghamrawy KA, Zawam HZ, Abdel-Azim H, Haggag M**. Risk factors in intermediate and high-grade non-Hodgkin's lymphomas of adults: a need for a new staging system. *Anticancer Drugs*. 1991; 2(4):383-8.
-